According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
F. Perry Wilson, MD, MSCE, shares insights from a review of recent study results published in the New England Journal of Medicine examining duty-hours rules at 63 residency…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
Historically, high-sensitivity diagnostic testing for many common diseases consisted of sending samples to an offsite laboratory and potentially waiting hours or days before results were attained and shared…
A new technique makes cancerous tumors glow, which in turn makes it easier to fully remove them during surgery. Employing nanotechnology designed to administer small-molecule drugs, physician researchers…
A research team from Brazil evaluated the link between anxiety and depression — nonmotor symptoms of Parkinson’s disease (PD) — and freezing of gait. They found that roughly…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
